CYB003

CYB003 (deupsilocin) is Cybin's deuterated version of psilocin, the active metabolite that makes psilocybin mushrooms psychedelic. Deuteration is a chemistry trick that swaps a few hydrogen atoms for their heavier isotope, slowing liver metabolism and tightening the dose response, giving a shorter and more predictable trip than psilocybin itself. Cybin is running two Phase 3 trials in adjunctive major depressive disorder (MDD) against a placebo-controlled MADRS endpoint [1][2] - the largest psychedelic Phase 3 program in MDD specifically (Compass's program is in treatment-resistant depression). With Compass Pathways' COMP360 psilocybin clearing both of its Phase 3 trials in 2025-2026 with statistically significant but modest effect sizes (-3.6 to -3.8 MADRS points vs control) [3][10], CYB003 now has a clear quantitative bar to beat: a meaningfully larger placebo-adjusted delta than COMP360 to differentiate on efficacy and justify the deuteration-enabled shorter session. Cybin (Nasdaq: HELP, formerly CYBN) is well-capitalized into the H2 2026 readout.

CYB003 is a novel compound, never approved anywhere. The FDA granted it Breakthrough Therapy designation (BTD) in March 2024 on the strength of Phase 2 data, the most meaningful regulatory tailwind a Phase 3 psychedelic asset has received [4]. Two Phase 3 trials are actively recruiting: NCT06564818 (n=220, the lead key) and NCT06793397 (n=330, the confirmatory study), both placebo-controlled, both using the Montgomery-Åsberg Depression Rating Scale (MADRS) as the primary endpoint at 6 weeks [1][2]. Total program enrollment is 550 across the two trials. Cybin has guided to topline data from the lead Phase 3 (NCT06564818) in H2 2026, with the confirmatory readout (NCT06793397) following in 2027. The program is adjunctive - patients stay on their existing SSRI or SNRI - which is a smart commercial framing because it sidesteps the washout problem that Compass managed in monotherapy and matches how most depressed patients actually present in the clinic. Cybin transferred its U.S. listing from NYSE American to Nasdaq (ticker HELP) in January 2026 [11].

Psilocin works by jamming the gas pedal on serotonin 5-HT2A receptors, which sit on the surface of cortical neurons and, when activated, drive a transient burst of glutamate signaling and growth of new dendritic spines (the small protrusions on neurons where synapses form). In rodent models, a single dose grows new spines in the prefrontal cortex within 24 hours and the effect lasts at least a month - the leading hypothesis for why one or two psychedelic sessions can produce months of antidepressant benefit while daily SSRIs take weeks just to start working [5]. The genetics are messier than the pharmacology: variants of the HTR2A gene (single-nucleotide polymorphisms, or SNPs) show modest associations with depression and antidepressant response, but no single SNP is doing heavy lifting. The validation argument rests on pharmacology - every classical psychedelic hits 5-HT2A, and every classical psychedelic shows antidepressant signal in trials [6]. Deuteration doesn't change which receptor gets hit; it changes how long psilocin sticks around. Cybin's Phase 2 data showed a roughly 4-hour subjective experience versus 6+ hours for psilocybin, which is the entire commercial thesis - shorter chair time means fewer therapist hours per dose, which is the cost bottleneck for psychedelic-assisted therapy [7].

The lead Phase 3 (NCT06564818) randomizes 220 adults with moderate-to-severe MDD already on an SSRI or SNRI to a single 16 mg CYB003 dose plus a second 16 mg dose at week 3, versus placebo, with MADRS change at week 6 as the primary endpoint [1]. The confirmatory study (NCT06793397) expands to n=330 with the same design [2]. The 16 mg arm is the dose advancing to Phase 3, not the 12 mg arm originally tested. In the Phase 2b open-label-extension data Cybin released November 2024, the 16 mg cohort showed a ~22-point MADRS reduction from baseline at 4 months and ~23 points at 12 months after two doses (n=7), with 100% response and 71% remission at 12 months in that small arm [7]. Cross-arm separation versus placebo at the Phase 3 6-week primary endpoint will be the real test - the Phase 2 numbers are uncontrolled at long timepoints and the 16 mg arm is small. The 6-week primary timepoint is aggressive (earlier than many SSRI trials read out) and bets on the rapid-onset signal Cybin saw in Phase 2. The adjunctive design solves one problem (no SSRI washout, easier enrollment) and creates another (background SSRI noise could blunt the placebo-CYB003 delta). Functional unblinding is the elephant in the room: patients know if they tripped. Cybin is using an active-monitoring placebo and trained raters, but no psychedelic Phase 3 has cleanly solved this. Enrollment as of mid-2025 was tracking on plan per Cybin's Q1 FY2026 disclosures [8].

The model gives this drug a 10% chance of eventually being approved. That number starts from the historical approval rate for Phase 3 drugs in this area - about 51% - then adjusts based on ten specific facts about the trial and its sponsor. The biggest drags on the estimate are heavier-than-usual blinding, the sponsor's thin or weak approval record, weak earlier-phase results, and a randomized trial design. The remaining factors are near average for this stage, so they don't move the number much.

Efficacy risk is the placebo problem. Psychiatric trials are placebo-response factories, and psychedelic trials add functional unblinding on top - the patient who tripped knows they got drug, and that expectancy effect is hard to disentangle from pharmacology. Compass's two Phase 3 trials in treatment-resistant depression (TRD - patients who have failed at least two prior antidepressants, a harder population than MDD) both hit their primary endpoints in 2025 and Feb 2026 but with modest magnitudes of -3.6 and -3.8 MADRS points placebo-adjusted [3][10]. That's a 'pass on statistics, question on commercial' outcome - useful precedent that the FDA will accept these trials, but a warning that the placebo response in psychedelic trials compresses the deliverable delta. Safety risk is real but bounded: classical psychedelics carry transient blood pressure and heart rate increases, occasional acute anxiety during the session, and theoretical concerns about valvulopathy (heart valve damage) from chronic 5-HT2B agonism - though single-dose intermittent use largely sidesteps the chronic exposure issue. The bigger safety risk is rare psychiatric events (suicidality, prolonged dissociation) that small Phase 2 trials underpower for. Execution risk centers on the therapist-supported session model: every dose requires trained monitors and a controlled setting, and scaling that across dozens of sites is operationally heavier than a pill trial. Commercial risk is the open question. Even if CYB003 wins approval, REMS (Risk Evaluation and Mitigation Strategy - a mandatory FDA-imposed safety program that restricts how a drug can be dispensed, adding cost and access barriers) requirements, chair-time cost, and reimbursement uncertainty for psychedelic-assisted therapy could leave it niche. Spravato (esketamine) cleared a similar regulatory and REMS path and is on track for ~$1.2B in 2025 revenue per Johnson & Johnson's Q4 2025 earnings call [9] - that's the commercial ceiling to benchmark against, not the SSRI market.

Worth watching closely. Cybin is the cleanest pure-play on the psychedelic Phase 3 thesis in MDD specifically (Compass owns the TRD lane), and CYB003's lead-key readout in H2 2026 is one of the highest-information-content events in CNS biotech this year. The specific signal to watch: a placebo-adjusted MADRS delta of at least 6 points at week 6, with the lower bound of the 95% CI clearing 3 points. That's the threshold where CYB003 clearly beats the Compass benchmark of -3.6 to -3.8 and gives payers and prescribers something commercially meaningful. Anything in the Compass range or below and the deuteration-shorter-session thesis becomes a hard sell. The Compass priors are now both in: COMP005 (TRD, single 25 mg dose vs placebo, n=258, -3.6 MADRS at week 6, p<0.001) hit in 2025 [3]; COMP006 (TRD, 25 mg vs 10 mg vs 1 mg, n=581, -3.8 MADRS for 25 mg vs 1 mg at week 6, p<0.001) hit Feb 2026 [10]. Both passed but with modest magnitudes, which is the most important framing context for CYB003's readout. On the financials: Cybin reported $195M cash at Dec 31 2025 (Q3 FY2026), following a $175M registered direct offering in October 2025, giving roughly 21-22 months of runway covering through the H2 2026 readout and the 2027 confirmatory data [12]. Market cap is ~$257M against ~50M shares outstanding as of mid-2026, so the company effectively trades near cash - readout-binary equity. IP runway is strong: U.S. composition-of-matter patents (11,724,985 and 11,834,410) covering the deuterated tryptamine class extend exclusivity to at least 2041 [13], removing patent-cliff risk for the foreseeable commercial life. Watch for: Cybin's enrollment and safety updates through 2026; any quiet downsizing of the confirmatory trial is a tell.